Discovering what’s already out there in the fight against COVID-19

Accencio^® is currently applying our IP-GeoScape^® technology and methods to biological targets including RNA polymerase inhibitors, viral protease inhibitors, and TLR7/8 antagonists to identify drugs that could be retargeted for use in COVID-19 patients.

Our work involves identifying any relationships between the molecular structures of existing advanced clinical or marketed molecules and molecules claimed to/believed to interact with these validated COVID-19 biological targets, with the hope we might be able to offer some new ideas for effective COVID-19 treatments. Our focus areas include tackling viral replication, viral invasion and the cytokine storm. To see the results for each target, click below:

ACE2

Drug	Drug name	Original target
	MR-708
	ubenimex	Aminopeptidase inhibitor
	roquinimex	IL2 gene stimulator
	UK-369082	Thrombin-active fibrinolysis inhibitor inhibitor
	borofalan (10B)
	imidazolyl	ethanamide pentandioic acid
	antineoplaston	AS2-1 Glutamate receptor modulator
	124I-TLX-101	L-type amino acid transporter 1 inhibitor
	131I-TLX-101	L-type amino acid transporter 1 inhibitor
	Sch-42495	Endopeptidase inhibitor
	iofolastat	I 123 Glutamate carboxypeptidase II inhibitor
	laquinimod	Aryl hydrocarbon receptor agonist
	SC-49992	GP IIb IIIa antagonist
	tasquinimod	S100 calcium binding protein A9 modulator
	acetylleucine
	nateglinide	Calcium channel stimulator; Potassium channel inhibitor
	N,N`-diacetyl-L-cystine
	nicousamide	TGF-beta activated kinase-1 inhibitor

CXCR3

Drug	Drug name	Original target
	remacemide	NMDA receptor antagonist

IL6

Drug	Drug name	Original target
	temanogrel	5-HT 2a receptor inverse agonist

TLR7 Agonists

Drug	Drug name	Original target
	epetirimod
	BIIB-021	Hsp 90 inhibitor
	tenofovir	Reverse transcriptase inhibitor
	tenofovir exalidex	Reverse transcriptase inhibitor
	tenofovir disoproxil	Reverse transcriptase inhibitor

TLR7 Antagonists

Drug	Drug name	Original target
	RG-7166